Global Non-muscle Invasive Bladder Cancer Market to 2030 - Insights, Epidemiology and Forecast -

DUBLIN--()--The "Non-muscle Invasive Bladder Cancer (NMIBC) - Market Insights, Epidemiology and Forecast to 2030" report has been added to's offering.

This report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The NMIBC market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM NMIBC market size from 2017 to 2030. The report also covers current NMIBC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Non-muscle Invasive Bladder Cancer (NMIBC) Diagnosis

NMIBC is usually diagnosed with cystoscopic evaluation. Upon diagnosis, the location, number, and morphology of the tumors are recorded. Urinary cytology and upper tract imaging is performed to assess for extravesical urothelial tumors and staging purposes. The common diagnosis method used include cystoscopy, urine cytology, imaging, rigid cystoscopy (Transurethral resection of bladder tumor (TURBT) and blue light cytoscopy).

Non-muscle Invasive Bladder Cancer (NMIBC) Treatment

The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC. Transurethral resection of bladder tumor (TURBT) with or without intravesical therapy, such as mitomycin C (MMC) or Bacillus Calmette-Guerin (BCG), is the current standard of treatment for NMIBC. Intravesical BCG is commonly used as an adjuvant treatment after TURBT for intermediate-high-risk NMIBC. Local and systemic side effects are common with BCG and can lead to discontinuation of therapy in up to 20% of patients. However, up to 50% of patients fail BCG, significantly increasing the risk of progression and death. Patients who have failed BCG therapy require radical cystectomy with urinary diversion or chemotherapy and radiation, both of which are associated with considerable morbidity.

The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, intravesical immunotherapy (BCG) and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Most people with non-muscle-invasive bladder cancer have an operation called transurethral resection of bladder tumor (TURBT). Cystoscopic tumor resection is preferred in the patients wherein there is a removal of any cancer cells that can be seen at transurethral resection of bladder tumor (TURBT). Moreover, Keytruda (pembrolizumab) is the only approved drug for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

The market report gives a thorough understanding of NMIBC by including details such as disease definition, causes, mechanism, biomarkers, and diagnosis.

Key Findings

  • In the 7MM, the total diagnosed prevalent population of NMIBC was estimated to be 533,263 cases in 2017, which is expected to increase in the forecast period
  • The United States accounted for the maximum diagnosed prevalent population among the 7MM in 2017.
  • In EU5 countries, Germany accounted for the highest diagnosed cases of NMIBC while United Kingdom had the lowest diagnosed prevalent population in 2017.
  • In the United States, there were 6,841, 58,791, 125,919 and 22,234 cases for >44, 45-64, 65-84 and >85 years, in 2017 which is expected to rise in the forecast period.
  • There are different stages in which NMIBC is classified which include Ta (lowest stage), Stage Tis and Stage T1. Over half of patients with low-grade Ta cancers will have a tumor recurrence. In 2017, the diagnosed prevalent population of stage Ta, low grade NMIBC was 134,684 and stage Ta, high grade NMIBC was 14,965 in the United States.
  • In 2017, the diagnosed prevalent population of high risk NMIBC was 26,366 and low risk NMIBC was 48,325 in Japan.

Scope of the Report

  • The report covers the descriptive overview of NMIBC, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the NMIBC epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for NMIBC is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of NMIBC market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM NMIBC market.

Report Highlights

  • NMIBC market is anticipated to increase at a CAGR of 7.98% for the study period 2017-2030.
  • The United States accounted for more than half (50.69%) of the market share in the 7MM.
  • Adstiladrin is projected to lead the market with the largest market share in 2030.
  • In the coming years, NMIBC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence NMIBC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for NMIBC. Launch of emerging therapies will significantly impact the NMIBC market.
  • An in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • FKD Therapies Oy/Ferring Pharmaceuticals
  • Merck
  • Viventia Bio/Sesen Bio
  • CG Oncology
  • ImmunityBio/Altor Biosciences
  • Theralase

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900